title: Time to define leprosy elimination as zero leprosy transmission?
authors.affiliation: Institute of Applied Health Sciences, University of Aberdeen, Aberdeen AB252ZD, UK. Electronic address: cairns.smith@btinternet.com.
authors.forename: Cairns S
authors.initials: CS
authors.lastname: Smith
authors.affiliation: Novartis Foundation, Basel, Switzerland.
authors.forename: Ann
authors.initials: A
authors.lastname: Aerts
authors.affiliation: Sasakawa Memorial Health Foundation, Akasaka Minato-ku, Tokyo, Japan.
authors.forename: Etsuko
authors.initials: E
authors.lastname: Kita
authors.affiliation: International Leprosy Association, Instituto Lauro de Souza Lima, Bauru, Brazil.
authors.forename: Marcos
authors.initials: M
authors.lastname: Virmond
mesh_terms: D014943:Global Health; D006801:Humans; D007917:Leprostatic Agents / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission*; D009166:Mycobacterium leprae / Q000187:drug effects / Q000502:physiology*; D014944:World Health Organization
chemical_list: D007917:Leprostatic Agents